Xbrane Biopharma Valuation

Is XBRANE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XBRANE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XBRANE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XBRANE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XBRANE?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for XBRANE. This is calculated by dividing XBRANE's market cap by their current preferred multiple.
What is XBRANE's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 340.31m

XBRANE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.4x
Enterprise Value/EBITDA	-1.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does XBRANE's PS Ratio compare to its peers?

The above table shows the PS ratio for XBRANE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	15.8x
SENZA SenzaGen	3.8x	30.6%	SEK 215.4m
ATORX Alligator Bioscience	19.7x	-8.0%	SEK 530.6m
SANION Saniona	23.2x	35.3%	SEK 428.8m
IMMU Mendus	16.7x	23.4%	SEK 511.7m
XBRANE Xbrane Biopharma	1.7x	61.1%	SEK 340.3m

Price-To-Sales vs Peers: XBRANE is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (15.8x).

Price to Earnings Ratio vs Industry

How does XBRANE's PE Ratio compare vs other companies in the SE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	48.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	48.4%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: XBRANE is good value based on its Price-To-Sales Ratio (1.7x) compared to the Swedish Biotechs industry average (12.5x).

Price to Sales Ratio vs Fair Ratio

What is XBRANE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XBRANE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.7x
Fair PS Ratio	20.8x

Price-To-Sales vs Fair Ratio: XBRANE is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (20.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XBRANE forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 0.22	SEK 0.45 +102.2%	33.3%	SEK 0.60	SEK 0.30	n/a	2
Oct ’25	SEK 0.18	SEK 0.45 +145.4%	33.3%	SEK 0.60	SEK 0.30	n/a	2
Sep ’25	SEK 0.15	SEK 0.45 +202.0%	33.3%	SEK 0.60	SEK 0.30	n/a	2
Aug ’25	SEK 0.18	SEK 0.60 +226.8%	8.3%	SEK 0.65	SEK 0.55	n/a	2
Jul ’25	SEK 0.25	SEK 0.60 +136.2%	8.3%	SEK 0.65	SEK 0.55	n/a	2
Jun ’25	SEK 0.30	SEK 0.60 +101.3%	8.3%	SEK 0.65	SEK 0.55	n/a	2
May ’25	SEK 0.22	SEK 0.63 +188.7%	4.0%	SEK 0.65	SEK 0.60	n/a	2
Mar ’25	SEK 0.68	SEK 61.38 +8,925.7%	98.8%	SEK 122.00	SEK 0.75	n/a	2
Feb ’25	SEK 1.61	SEK 84.00 +5,117.4%	45.2%	SEK 122.00	SEK 46.00	n/a	2
Jan ’25	SEK 10.00	SEK 84.00 +740.0%	45.2%	SEK 122.00	SEK 46.00	n/a	2
Dec ’24	SEK 7.51	SEK 116.00 +1,444.6%	5.2%	SEK 122.00	SEK 110.00	n/a	2
Nov ’24	SEK 22.70	SEK 116.00 +411.0%	5.2%	SEK 122.00	SEK 110.00	SEK 0.23	2
Oct ’24	SEK 27.20	SEK 116.00 +326.5%	5.2%	SEK 122.00	SEK 110.00	SEK 0.18	2
Sep ’24	SEK 34.65	SEK 116.00 +234.8%	5.2%	SEK 122.00	SEK 110.00	SEK 0.15	2
Jul ’24	SEK 77.20	SEK 217.50 +181.7%	26.4%	SEK 275.00	SEK 160.00	SEK 0.25	2
Jun ’24	SEK 80.60	SEK 224.00 +177.9%	22.8%	SEK 275.00	SEK 173.00	SEK 0.30	2
May ’24	SEK 93.20	SEK 224.00 +140.3%	22.8%	SEK 275.00	SEK 173.00	SEK 0.22	2
Apr ’24	SEK 85.90	SEK 224.00 +160.8%	22.8%	SEK 275.00	SEK 173.00	SEK 0.30	2
Mar ’24	SEK 83.70	SEK 224.00 +167.6%	22.8%	SEK 275.00	SEK 173.00	SEK 0.68	2
Feb ’24	SEK 101.80	SEK 224.00 +120.0%	22.8%	SEK 275.00	SEK 173.00	SEK 1.61	2
Jan ’24	SEK 82.10	SEK 224.00 +172.8%	22.8%	SEK 275.00	SEK 173.00	SEK 10.00	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.